Summary
Pemetrexed (PEM) is an antimetabolite drug that interferes with enzymes involved in DNA synthesis and also the folate-dependent metabolic processes necessary for DNA replication and homocysteine homeostasis. Continuation maintenance with PEM after induction therapy with PEM plus cisplatin has been the standard form of first-line chemotherapy for advanced non-squamous non-small cell lung cancer. The regimen has a low incidence of bone marrow suppression, and the incidences of anemia, leukopenia, neutropenia and thrombocytopenia exceeding grade 3 are less than 5%. Here we report a 68-year-old Japanese man with stage IIIB (cT4N3M0) lung adenocarcinoma who received 4 cycles of chemotherapy with PEM 500 mg/m2 and cisplatin 75 mg/m2 every three weeks, which resulted in a partial response, and then continued to receive maintenance PEM monotherapy. After 11 cycles of PEM maintenance therapy, the patient’s platelet count decreased, and progressed to pancytopenia within two months. A bone marrow puncture revealed replacement with fatty marrow. As other diseases possibly responsible for pancytopenia were ruled out, we diagnosed the patient as having aplastic anemia. This is the first reported case of aplastic anemia to have occurred during PEM therapy. Clinicians should bear in mind that PEM can potentially trigger severe pancytopenia, including aplastic anemia.
Similar content being viewed by others
References
Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol J-L, Bidoli P et al (2012) Maintenance therapy with PEM plus best supportive care versus placebo plus best supportive care after induction therapy with PEM plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247–255
Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Thamprasit T, Sirijirachai J et al (1997) Low drug attributability of aplastic anemia in Thailand. Blood 89:4034–4039
Bacigalupo A, Oneto R, Bruno B, Socié G, Passweg J, Locasciulli A et al (2000) Current results of bone marrow transplantation in patients with acquired severe aplastic anemia: report of the European Group for Blood and Marrow transplantation. Acta Haematol 103:19–25
Lim AYN, Gaffney K, Scott DGI (2005) Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology 44:1051–1055
Fernando GI, Sahar EM, Shiri S, Hazem A, Amer KS, Simon B, et al. (2014) Methotrexate-induced pancytopenia. Case Reports in Rheumatology 2014: 679580.
Kremer J, Galivan J, Streckfuss A, Kamen B (1986) Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29:832–835
Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA (1985) Formation of methotrexate polyglutamates in purified myeloid precursors cells from normal human bone marrow. J Clin Invest 75:1008–1014
Rosenblatt DS, Whitehead VM, Dupont MM, Vuchich MJ, Vera N (1978) Synthesis of methotrexate polyglutamates in cultured human cells. Mol Pharmacol 14:210–214
Robert A Brodsky, Richard J Jones (2005) Aplastic anaemia. Lancet 365: 1647–1656.
Parmaceuticals and Medical Devices Agency (2008)
Acknowledgements
There is no source to funding to acknowledge.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
For this type of study, formal consent is not required.
Rights and permissions
About this article
Cite this article
Matama, G., Tokito, T., Takeoka, H. et al. Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed. Invest New Drugs 35, 662–664 (2017). https://doi.org/10.1007/s10637-017-0462-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-017-0462-z